RxDoctor Payments Data

Amanda Nies, DO

Neurological Surgery · Holland, MINPI 1639307093

Payments from drug & device makers

$2,928in general payments, 2019–2025

Across 147 payments — averaging $19.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Biogen$347
  • Lilly USA, LLC$188
  • Lundbeck LLC$181
  • Teva Pharmaceuticals USA, Inc.$150
  • SK Life Science, Inc.$127
  • plus $566 from 15 others

What the payments were for

  • Speaking & faculty fees$231%
  • Food & beverage$2,84797%
  • Education$592%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,928 in reported general payments places this provider in the 45th percentile of 256 neurological surgery providers in Michigan.

See all neurological surgery providers in Michigan

Medicare billing

Part B allowed, 2024
$43,465
Medicare patients
205
Services billed
1,271

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VumerityDiroximel Fumarate24$209,329
UbrelvyUbrogepant78$94,287
GlatopaGlatiramer Acetate18$72,010
Emgality PenGalcanezumab-Gnlm79$56,338
Glatiramer Acetate20$48,734
XcopriCenobamate37$43,589
Dalfampridine ErDalfampridine51$40,106
OnfiClobazam18$36,500
Emgality SyringeGalcanezumab-Gnlm39$34,754
Nurtec OdtRimegepant Sulfate21$29,704
Aimovig AutoinjectorErenumab-Aooe28$25,991
Carbidopa-LevodopaCarbidopa/Levodopa245$17,652
Rivastigmine76$14,572
TopamaxTopiramate13$12,226
Lacosamide134$11,852

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity$347$209,32924 claims
AbbVieUbrelvy$1,369$94,28778 claims
SK Life Science, Inc.Xcopri$127$43,58937 claims
Lundbeck LLCOnfi$181$36,50018 claims
PfizerNurtec Odt$29$29,70421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 256 neurological surgery providers in Michigan.

Other neurological surgery in Holland

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →